Quest Diagnostics Incorporated (NYSE:DGX) Receives Consensus Recommendation of “Hold” from Analysts

Quest Diagnostics Incorporated (NYSE:DGXGet Free Report) has been given an average rating of “Hold” by the thirteen ratings firms that are presently covering the company, Marketbeat Ratings reports. Nine analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $154.92.

A number of research firms have issued reports on DGX. Piper Sandler increased their target price on shares of Quest Diagnostics from $145.00 to $150.00 and gave the company a “neutral” rating in a research note on Monday, July 29th. Evercore ISI began coverage on shares of Quest Diagnostics in a research note on Wednesday, August 28th. They set an “in-line” rating and a $165.00 price target for the company. Barclays raised their price target on shares of Quest Diagnostics from $144.00 to $154.00 and gave the stock an “equal weight” rating in a research note on Tuesday, August 27th. Citigroup upgraded shares of Quest Diagnostics from a “neutral” rating to a “buy” rating and raised their price target for the stock from $145.00 to $165.00 in a research note on Wednesday, July 10th. Finally, Robert W. Baird raised their price target on shares of Quest Diagnostics from $153.00 to $154.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 24th.

View Our Latest Stock Report on DGX

Insider Buying and Selling at Quest Diagnostics

In related news, SVP Karthik Kuppusamy sold 1,990 shares of the stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $153.26, for a total transaction of $304,987.40. Following the completion of the transaction, the senior vice president now directly owns 11,459 shares in the company, valued at approximately $1,756,206.34. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, SVP Karthik Kuppusamy sold 1,990 shares of the stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $153.26, for a total transaction of $304,987.40. Following the completion of the transaction, the senior vice president now directly owns 11,459 shares in the company, valued at approximately $1,756,206.34. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Mark E. Delaney sold 420 shares of the stock in a transaction dated Wednesday, July 24th. The stock was sold at an average price of $143.08, for a total value of $60,093.60. Following the transaction, the senior vice president now owns 5,019 shares of the company’s stock, valued at approximately $718,118.52. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.79% of the company’s stock.

Hedge Funds Weigh In On Quest Diagnostics

A number of institutional investors have recently added to or reduced their stakes in the company. Rothschild Investment LLC acquired a new position in shares of Quest Diagnostics in the second quarter valued at $26,000. Innealta Capital LLC bought a new position in Quest Diagnostics during the 2nd quarter worth $31,000. Larson Financial Group LLC lifted its holdings in shares of Quest Diagnostics by 77.5% during the second quarter. Larson Financial Group LLC now owns 229 shares of the medical research company’s stock worth $31,000 after buying an additional 100 shares in the last quarter. Riverview Trust Co acquired a new stake in shares of Quest Diagnostics during the first quarter worth $33,000. Finally, TruNorth Capital Management LLC acquired a new stake in shares of Quest Diagnostics during the second quarter worth $33,000. 88.06% of the stock is currently owned by institutional investors and hedge funds.

Quest Diagnostics Trading Up 0.2 %

NYSE DGX opened at $149.00 on Tuesday. Quest Diagnostics has a 1-year low of $120.87 and a 1-year high of $159.36. The company has a current ratio of 1.00, a quick ratio of 0.91 and a debt-to-equity ratio of 0.57. The company has a market capitalization of $16.55 billion, a PE ratio of 20.05, a price-to-earnings-growth ratio of 2.45 and a beta of 0.89. The firm’s fifty day simple moving average is $152.57 and its 200-day simple moving average is $143.64.

Quest Diagnostics (NYSE:DGXGet Free Report) last posted its earnings results on Tuesday, July 23rd. The medical research company reported $2.35 EPS for the quarter, topping the consensus estimate of $2.31 by $0.04. The firm had revenue of $2.40 billion for the quarter, compared to the consensus estimate of $2.39 billion. Quest Diagnostics had a net margin of 8.99% and a return on equity of 15.35%. The business’s quarterly revenue was up 2.5% on a year-over-year basis. During the same period in the prior year, the business posted $2.30 earnings per share. As a group, sell-side analysts anticipate that Quest Diagnostics will post 8.89 earnings per share for the current fiscal year.

Quest Diagnostics Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, October 21st. Shareholders of record on Friday, October 4th will be paid a $0.75 dividend. This represents a $3.00 annualized dividend and a yield of 2.01%. The ex-dividend date is Friday, October 4th. Quest Diagnostics’s payout ratio is 40.38%.

Quest Diagnostics Company Profile

(Get Free Report

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.

Read More

Analyst Recommendations for Quest Diagnostics (NYSE:DGX)

Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.